Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's product candidates comprise Symjepi Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of fluticasone for the treatment of asthma; beclomethasone, a metered dose inhaler product for the asthma; and naloxone injection product candidates for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: adamispharmaceuticals.com
| Date | Price Target | Rating | Analyst |
|---|
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company's special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as we
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company's fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its websi
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today reported financial results for the third quarter of 2022 and provided an update on recent corporate developments. Process Update In October, the Company announced that it had initiated a process to explore a range of strategic and financing alternatives and had retained an investment bank to assist in evaluating certain alternatives focused on maximizing stockholder value. Potential
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, November 14, 2022 at 2:00 p.m. PT to discuss its financial and operating results for the third quarter 2022 as well as provide a corporate update. The company's third quarter 2022 financial results news release is expected to be available after 1 p.m. PT on November 14, 2022, and on its website. Event: Adamis Pharmaceuticals Third Quarter 2022 Financial Results Conference Call Da
SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today reported financial results for the second quarter of 2022 and provided an update on recent corporate developments. "I committed to the CEO role in May because I could see beyond Adamis' current position to where it could go. I knew the Company had strong assets which we could leverage to unlock shareholder value," said David J. Marguglio, CEO of Adamis. "We have two FDA-approved prod
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Wednesday, August 10, 2022 at 1:30 p.m. Pacific Time to discuss its financial and operating results for the second quarter 2022 as well as provide a corporate update. The company's press release concerning its second quarter 2022 financial results is expected to be available after 1 p.m. Pacific Time on August 10, 2022, and on its website. Event: Adamis Pharmaceuticals Second Quarter 2
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the quarter ending March 31, 2022. Product and Pipeline Updates and Other Corporate Developments ZIMHI According to the Centers for Disease Control and Prevention (CDC), drug overdoses resulted in over 108,000 deaths in the U.S. over the most recent 12 months of data. Two thirds of these involved fentanyl.Our U.S. commercial partner, US WorldMeds, commercially launched our high dose naloxone product, ZIMHI, at th
SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 16, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2022 as well as provide a business update. The company's press release concerning its first quarter 2022 financial results is expected to be available after 1 p.m. Pacific Time on May 16, 2022, and on its website. Event: Adamis Pharmaceuticals First Quarter 2022 Financial Result
SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the year ended December 31, 2021. "We managed to achieve all of our internal objectives for 2021," stated Dennis J. Carlo, Ph.D., President and Chief Executive Officer of Adamis Pharmaceuticals. "Included among them, we began enrolling patients in a Phase 2/3 clinical trial evaluating Tempol as a treatment of COVID-19, resubmitted our NDA for ZIMHI and subsequently received FDA approval." Product and Pipeline Upd
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 31, 2022 at 2 p.m. Pacific Time to discuss its financial and operating results for the fourth quarter and full year 2021 as well as provide a business update. The company's press release concerning its fourth quarter and 2021 financial results is expected to be available after 1 p.m. Pacific Time on March 31, 2022, and on its website. The company also expects to file its a
SC 13G/A - DMK PHARMACEUTICALS Corp (0000887247) (Subject)
SC 13D/A - DMK PHARMACEUTICALS Corp (0000887247) (Subject)
SC 13G - Adamis Pharmaceuticals Corp (0000887247) (Subject)
SC 13D - Adamis Pharmaceuticals Corp (0000887247) (Subject)
SC 13G/A - Adamis Pharmaceuticals Corp (0000887247) (Subject)
SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 Corporate Highlights In May, the Company closed the merger with DMK Pharmaceuticals Corporation (DMK), a private, clinical-stage biotechnology company at the forefront of endorphin-inspired drug design focused on developing novel treatments for opioid use disorder and other neuro-based diseases. Ebrahim Versi, MD, PhD, CEO of DMK, was named CEO of Adamis and Chairman of the Board of Directors. David J. Margu
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $1.35. The common warrants are immediately exercisable at a price of $1.35 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants were only purchasable together in this offering, but
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit. Each unit consists of one share of common stock (or a prefunded warrant in lieu thereof) and one warrant to purchase one share of common stock. The common warrants will be immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants can only be purchased together in this offering, b
SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Albert Dahan, MD, PhD, a world expert on opioid-induced respiratory depression (opioid overdose) and professor of anesthesiology at the University. Dr. Dahan has been working with the FDA since 2020 to understand better methods of reversing fentanyl overdoses. "Data presented from our recent study conducted in collaboration with the U.S. Food and Drug Ad
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD) (#R41AA030226). Different types of drug addiction fall under the umbrella term of substance use disorders or SUD. Physicians have a better understanding of SUD and given recent research findings we now know that these con
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo Versi, MD, PhD, CEO of Adamis Pharmaceuticals is proud and excited to have participated in the White House Roundtable with Opioid Reversal Product Manufacturers, hosted by White House Office of National Drug Control Policy Director, Dr. Rahul Gupta, White House Domestic Policy Council Advisor Neera Tanden, U.S. Assistant Secretary for Health Admiral Rachel Levine, and U.S. Assistant Secretary for Mental Health and Substance Use Dr. Miriam E. Delphin-Rittmon. Dr. Gupta is the first medical doctor to ever lead the White House O
DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined companyCombined company will have commercial products and a library of development candidates, including two clinical stage programsDPI-125, the lead development program, is a clinical stage therapeutic under investigation for the treatment of opioid use disorder SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its merger with DMK Pharmaceuticals Corporation. The combined, publicly traded company will focus its efforts on increasing sales of Adamis' commercial products and advancing DMK's l
SAN DIEGO, May 19, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time. Adamis' common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") under the symbol "ADMP" and will begin trading on a split-adjusted basis when the market opens on May 22, 2023. The reverse stock split is primarily intended to increase the market price per share of the Company's common stock to regain compliance with the minimum bid price requirement for maintaining its listin
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company's special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as we
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced financial results for the full year ended December 31, 2022, and provided an update on recent corporate developments. General Corporate Highlights Merger Agreement with DMK Pharmaceuticals In October 2022, Adamis announced that it had initiated a process to explore a range of strategic and financing alternatives and had retained an investment bank to assist in evaluating certain alternatives focu
4 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)
3 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)
4 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)
3 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)
4 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)
4 - Adamis Pharmaceuticals Corp (0000887247) (Issuer)
4 - Adamis Pharmaceuticals Corp (0000887247) (Issuer)
4 - Adamis Pharmaceuticals Corp (0000887247) (Issuer)
3 - Adamis Pharmaceuticals Corp (0000887247) (Issuer)
3 - Adamis Pharmaceuticals Corp (0000887247) (Issuer)
Maxim Group resumed coverage of Adamis Pharmaceuticals with a rating of Hold
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from Chief Executive Officer David J. Marguglio. ADAMIS HAS NEW LEADERSHIP COMMITTED TO ENHANCING SHAREHOLDER VALUE YOUR SUPPORT AT THE ANNUAL MEETING IS CRITICAL TO OUR FUTURE SUCCESS July 21, 2022 Dear Fellow Stockholder: Thank you for your ongoing investment in Adamis Pharmaceuticals Corporation ("we," "our," "Adamis" or the "Company"). Like
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Vickie Reed as a new director and member of the company's board of directors. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Ms. Reed to the Board and look forward to working with her to pursue long-term stockholder value. Her substantial expertise as a healthcare executive in financial leadership roles at several public companies, and extensive background in finance and accounting, combined with her experience as a director of another public life science company, should allow her to have an immediate positive impact as Adamis exec
David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced a leadership transition plan to support its efforts to unlock long-term growth and value creation opportunities: David J. Marguglio, Co-Founder and Chief Business Officer, has been appointed President and Chief Executive Officer, effective immediately. Dennis J. Carlo, Ph.D., has re
SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022. "Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided valuable insight and counsel to the board as well as our staff. He has been an exemplary leader through the challenges the company has faced and has been fair and unwavering in his support for Adamis," said Adamis' CEO and President, Dr. Dennis J. Carlo. "We admire Dick for his work ethic and wish him all the best in his retirement." About Adamis Pharmaceuticals Adamis Pharmaceuticals Corporation i
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company's board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Dr. Desai to the Board and look forward to working with her to pursue long-term value creation. Her substantial expertise in international pharmaceutical licensing, combined with her background in drug development and commercialization will help us refine corporate strategy to maximize our product pipeline. I
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that David C. Benedicto, who has been serving as the Company's Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr. Hopkins is departing to pursue new opportunities after serving the Company for the past 14 years. Management has established a comprehensive transition plan to maintain full continuity across all finance functions as Mr. Hopkins departs. Dr. Dennis J. Carlo, Chief Executive Officer of Adamis, commented: "David has been an important member of our finance team since he joined Adamis nearly seven years ago. In a
Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis" or the "Company") today announced that based on the Inspector of Election's certified results from the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"), each of the Company's nominees – Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams – have been re-elected to the Board of Directors (the "Board"). According to the Inspector of Election's report, stockholders approved all other proposals considered at the Annual Meeting, includ
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
DEFA14A - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
DEFA14A - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
DEFA14A - DMK PHARMACEUTICALS Corp (0000887247) (Filer)
Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer
Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling
On Thursday, 283 companies set new 52-week lows. 52-Week Low Highlights: The largest company by market cap to set a new 52-week low was Pfizer (NYSE:PFE). Blue Star Foods (NASDAQ:BSFC) was the smallest company when considering market cap to set a new 52-week low. Edible Garden AG (NASDAQ:EDBL) made the largest move down on the session, with shares plummeting 34.15% to reach its 52-week low. Almacenes Exito (NYSE:EXTO) shares bounced back the most, actually rising 0.0% after hiting a new 52-week low. The following stocks created new 52-week lows on Thursday: Pfizer (NYSE:PFE) shares made a new 52-week low of $34.04 on Thursday. The stock was down 0.74% for the day. Walt Disney
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the company changed its name to DMK Pharmaceuticals Corporation in order to better reflect its new strategic focus on advancing small molecules for the treatment of substance use disorders. In conjunction with the name change, the company's common stock is expected to trade under the new Nasdaq ticker symbol "DMK" on or about September 8, 2023. The CUSIP number for the common stock, 00547W307, will remain unchanged. "The new DMK Pharmaceuticals is committed to developing groundbreaking and innovative therapies to establish itself as a leader in the treatment of substance abuse i
On Tuesday morning, 164 companies achieved new lows for the year. 52-Week Low Highlights: NextEra Energy (NYSE:NEE) was the largest firm by market cap to set a new 52-week low. SenesTech (NASDAQ:SNES) was the smallest company in terms of market cap to set a new 52-week low. WeWork (NYSE:WE) saw the largest move of the companies, as shares plummetted 3189.55% to hit a new 52-week low. Tarena International (NASDAQ:TEDU)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low. Here is a list of stocks that set new 52-week lows on Tuesday: NextEra Energy (NYSE:NEE) stock dropped to a yearly low on Tuesday of $65.95. Shares traded down 1.0
Adamis Pharmaceuticals (NASDAQ:ADMP) reported quarterly losses of $(3.40) per share. This is a 19.05 percent increase over losses of $(4.20) per share from the same period last year. The company reported $6.95 thousand in sales this quarter. This is a 82.57 percent decrease over sales of $39.85 thousand the same period last year.
During the Friday's sesion, 157 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Corteva (NYSE:CTVA) was the biggest company on a market cap basis to set a new 52-week low. The smallest company by market cap to hit a new 52-week low was American Rebel Holdings (NASDAQ:AREB). Mullen Automotive (NASDAQ:MULN) made the largest move down on the session, with shares plummeting 815.93% to reach its 52-week low. BNY Mellon Strategic (NYSE:LEO) saw the sharpest rebound, as shares ascended 0.0%, reversing after hiting a new 52-week low. The following stocks created new 52-week lows on Friday: Corteva (NYSE:CTVA) shares hit a yearly low of $52.02. The stock
On Wednesday, 155 companies set new 52-week lows. Interesting Points From Today's 52-Week Highs And Lows: The largest company by market cap to set a new 52-week low was Estee Lauder Cos (NYSE:EL). The smallest company by market cap to set a new 52-week low was SenesTech (NASDAQ:SNES). Siyata Mobile (NASDAQ:SYTA)'s stock fell the most, as it traded down 7658.62% to reach a new 52-week low. Sutro Biopharma (NASDAQ:STRO) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low. The following stocks set new 52-week lows on Wednesday: Estee Lauder Cos (NYSE:EL) stock broke to a new 52-week low of $165.94 on Wednesday. Sha
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks each week that are just under the surface and warrant attention. The index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors and casual readers should watch them. Here is a look at the Benzinga Stock Whisper Index for the week of Aug. 5, 2023. Tupperware Brands Corporation (NYSE:TUP): The well-known consumer prod
Gainers T2 Biosystems (NASDAQ:TTOO) stock increased by 63.0% to $0.4 during Thursday's regular session. The current volume of 381.1 million shares is 611.2% of T2 Biosystems's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $114.9 million. Bluejay Diagnostics (NASDAQ:BJDX) stock increased by 60.43% to $8.76. Bluejay Diagnostics's stock is trading at a volume of 9.8 million shares as of 13:30 EST. This is 2506.7% of its average full-day volume over the last 100 days. The company's market cap stands at $8.9 million. Corcept Therapeutics (NASDAQ:CORT) stock rose 25.5% to $31.39. As of 13:30 EST, this security is t
Gainers Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares jumped 75% to $9.60. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) gained 60.2% to $2.13. Adamis Pharmaceuticals shares declined around 67% on Wednesday after the company reported pricing of $8 million public offering of 5.93 million units at a price of $1.35 per unit. Traeger, Inc. (NYSE:COOK) shares climbed 43.2% to $5.90 after the company posted upbeat quarterly results. T2 Biosystems, Inc. (NASDAQ:TTOO) surged 37% to $0.3324 after gaining 54% on Wednesday. T2 Biosystems recently announced it received an extension to comply with the Nasdaq listing requirements. FOXO Technologies Inc. (NYSE:FOXO) gained 37.7% to $0.20. TC B